Mechanisms of antineoplastic action of somatostatin analogs.
about
Somatostatin receptor (SSTR) expression and function in normal and leukaemic T-cells. Evidence for selective effects on adhesion to extracellular matrix components via SSTR2 and/or 3Medical treatment for gastro-entero-pancreatic neuroendocrine tumoursPhase I trial of combination of FOLFIRI and pasireotide, a somatostatin analogue, in advanced gastrointestinal malignancies.Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives.Bioactive unnatural somatostatin analogues through bioorthogonal iodo- and ethynyl-disulfide intercalators.Expression of somatostatin, cortistatin, and somatostatin receptors in human monocytes, macrophages, and dendritic cells.Insulin-like growth factors and neoplasia.Somatostatins and their role in thyroid cancer.Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials.Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro.Association between somatostatin receptor 5 gene polymorphisms and pancreatic cancer risk and survival.Lipophilization of somatostatin analog RC-160 with long chain fatty acid improves its antiproliferative and antiangiogenic activity in vitro.Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238.Pancreatic cancer - a continuing challenge in oncology.Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.Inhibitory effect of octreotide on gastric cancer growth via MAPK pathway.Neurogenesis and neuronal regeneration in the adult fish brain.Alteration of somatostatin receptor subtype 2 gene expression in pancreatic tumor angiogenesisPhase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer.Limited neuropeptide Y precursor processing in unfavourable metastatic neuroblastoma tumoursLocalisation of somatostatin and somatostatin receptors in benign and malignant ovarian tumoursAntagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers.Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer.The insulin-like growth factor system and its receptors: A potential novel anticancer target.Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives.Somatostatin and somatostatin receptors: implications for neoplastic growth and cancer biology.Effect of GnRH analogues and octreotide treatment on apoptosis and the cell proliferation of endometrium adenocarcinoma cell lines.Improvement of drug-like properties of peptides: the somatostatin paradigm.High expression of somatostatin receptor subtype 2 (sst2) in medulloblastoma: implications for diagnosis and therapy.Synthesis and in vitro antitumor activity of new octapeptide analogs of somatostatin containing unnatural amino acids.Synthesis and evaluation of biodegradable PCL/PEG nanoparticles for neuroendocrine tumor targeted delivery of somatostatin analog.Expression of somatostatin receptors in human melanoma cell lines: effect of two different somatostatin analogues, octreotide and SOM230, on cell proliferation.Effects of non-cytotoxic drugs on the growth of multidrug-resistance human gastric carcinoma cell line.Targeted therapy with a cytotoxic somatostatin analog, AN-238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR-1.Somatostatin receptor subtype 2-mediated scintigraphy and localization using (99m)Tc-HYNIC-Tyr(3)-octreotide in human hepatocellular carcinoma-bearing nude miceEnhanced inhibitive effects of combination of rofecoxib and octreotide on the growth of human gastric cancer.Expression of somatostatin receptors in normal and cirrhotic human liver and in hepatocellular carcinoma.IGF-I stimulates proliferation of spontaneously immortalized human keratinocytes (HACAT) by autocrine/paracrine mechanisms.Antineoplastic effects of octreotide on human gallbladder cancer cells in vitro.Selective stimulation of somatostatin receptor subtypes: differential effects on Ras/MAP kinase pathway and cell proliferation in human neuroblastoma cells.
P2860
Q24681476-582FF745-4DA2-4636-9867-8D74A015B280Q26751659-7EB86A77-50BA-4546-8894-1804033D79C3Q33425196-5779CFB8-C4F9-4F2E-B37B-5DF50678F98EQ33753449-FAE9E26A-123A-47A6-A0FB-89D435872FCEQ33958534-BDF9770F-F6AC-466E-9541-5578359134D9Q34189365-ACC38DAB-403F-45CF-B41A-6089CDFA6927Q34330521-76A01013-C063-4E71-8430-8FAC7EDD9528Q34626992-F47BF6D1-D35C-4047-ABFE-3D30B1A3244DQ35006620-85A40287-1CFB-4406-B552-56556FE143FEQ35066088-B7524C98-4122-4748-BEB1-292047B09015Q35103474-0AF34B1D-4628-4C27-A075-7CC12519BAD6Q35107573-719767F2-3B89-41F6-8BCE-C532BDA79352Q35199203-6E72ABA4-14D8-43F6-B6A5-C671FADDF71DQ35613016-3B64483D-5820-40F9-BC65-0B56FDC11FD4Q35891113-ECD55096-5B57-4D60-BFF0-E1F3CADAE88BQ36309149-2D2BE83E-7C62-4A65-B6C0-5494A9D85232Q36389396-341981B8-1FDE-4F45-8F66-C735C1BCDE50Q36474555-AFD35DA2-335A-4FB6-AA31-5AD09EDBA4F6Q36619058-6DB8ABB8-2848-4A28-9B07-D736069E6133Q36621739-B88ACF73-8DF6-407F-A1CC-DCE40DF177EEQ36624229-BC4CC792-D917-47F5-B6D3-F3A68EA0BBBDQ36641767-1812ADCB-CE0F-4150-A26B-E62E65FF493DQ36677464-C4B1CB1F-691B-4F03-A8F0-01763AA46942Q37307864-99DB891E-08A4-4A39-94FB-97B9CA31E012Q37564373-2DBEAFB3-742E-4E94-A994-F1DB259C4DBBQ37579225-533F7805-79BA-4507-8575-DA0D8E111243Q37611249-1B225068-370E-469B-82FC-46989B70C50EQ38028559-1CD5869C-F114-4E72-9292-575D8C0133EFQ38325005-4DAB8B47-FBA2-419D-BEA0-39C914626D1FQ38912617-9501CF05-BF5C-42D3-85EA-75EAB4B011F1Q39377293-71E3A7A7-3E69-4B2F-9F36-A0E3A53001C7Q39741277-D15471F6-6892-4274-B13C-D026162E1EB0Q39854865-39E76013-4658-4784-9F57-86E163C696D6Q40392702-10AE1E6C-7B6D-45DD-AD42-68B1C7E59C96Q40403100-20B1D38D-F60E-42BA-BF4C-A25621F78109Q40513039-2CD0614D-B46E-4F6B-ACE3-383CED5A3354Q40537154-F931073B-7E5F-4A51-A996-E95772E8F60AQ40558607-EE81BA7C-5585-48DE-8E6D-06E3B42F492DQ40571857-796F6053-D937-4D3A-AE78-E46B1AD486E0Q40852282-280D29F2-CD19-4EED-B9E5-620514B73E58
P2860
Mechanisms of antineoplastic action of somatostatin analogs.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Mechanisms of antineoplastic action of somatostatin analogs.
@en
type
label
Mechanisms of antineoplastic action of somatostatin analogs.
@en
prefLabel
Mechanisms of antineoplastic action of somatostatin analogs.
@en
P1476
Mechanisms of antineoplastic action of somatostatin analogs.
@en
P2093
P304
P356
10.3181/00379727-217-44216
P577
1998-02-01T00:00:00Z